Cadrenal Therapeutics, Inc. (CVKD): Nasdaq/NYSE listing notice — Cadrenal Therapeutics receives 180-day Nasdaq extension to Sept 3, 2024 to meet $1 bid price rule

Cadrenal Therapeutics, Inc.

Nasdaq granted a 180-day extension until September 3, 2024 to regain minimum $1.00 closing bid price.
Compliance requires $1.00 bid price for at least 10 consecutive business days; can be extended up to 20 days.
Non-compliance was first disclosed on September 6, 2023; stock continues trading on Nasdaq under CVKD.
Company may consider a reverse stock split if it cannot meet the price requirement by the deadline.
If compliance not regained by Sept 3, 2024, Nasdaq will delist; company could appeal to hearings panel.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cadrenal Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 5, 2024, the Company received written notification from Nasdaq granting the Company's request for a 180-day extension or until September 3, 2024 to regain compliance with the Rule. Compliance is generally achieved by meeting the minimum bid price of $1.00 per share (the “Price Requirement”) for a minimum of 10 consecutive business days. However, the Staff may, in its discretion, require a Company to satisfy the applicable Price Requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company h

View on SEC.gov

Browse all listing & compliance notices →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-020181

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.